Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil. by Chou, T C et al.
Vol. 31, No. 9ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1987, p. 1355-1358
0066-4804/87/091355-04$02.00/0
Copyright © 1987, American Society for Microbiology
Synthesis and Biological Effects of
2'-Fluoro-5-Ethyl-1- 1-D-Arabinofuranosyluracil
TING-CHAO CHOU,'* XIANG-BIN KONG,' MICHAEL P. FANUCCHI,1 YUNG-CHI CHENG,2
KIYOBUMI TAKAHASHI,3 KYOICHI A. WATANABE,3 AND JACK J. FOX3
Laboratories of Pharmacology' and Organic Chemistry,3 Sloan-Kettering Institute for Cancer Research, Memorial Sloan-
Kettering Cancer Center, New York, New York 10021, and Department of Pharmacology and Medicine, University of
North Carolina, Chapel Hill, North Carolina 275142
Received 24 April 1987/Accepted 1 July 1987
2'-Fluoro-5-ethyl-1-4-D-arabinofuranosyluracil (FEAU) was synthesized, and its biological activities were
compared with those of 2'-fluoro-5-methyl-1-oi-D-arabinofuranosyluracil (FMAU). Earlier studies indicated
that both compounds showed potent anti-herpes simplex virus activity, with a 50% effective dose (EDSO) of
<0.25 ,uM. In the present study the cell growth inhibitory activity of FEAU (ED50, 200 to 2,060 ,uM) was found
to be about 100-fold less than that of FMAU. With an ED50 ranging from 630 to 3,700 ,uM, FEAU only weakly
inhibited thymidine incorporation into DNA, as compared with FMAU with an ED50 of 9 to 28 ,uM. Following
exposure to [2-'4C]FEAU (100 ,uM), 0.48 pmol/106 cells per h was incorporated into the DNA of herpes simplex
virus type 1-infected Vero cells, whereas no detectable incorporation was found in uninfected Vero cells or
L1210 cells. The Ki of FEAU for thymidine kinase purified from human leukemic cells was >150 ,uM. For
herpes simplex virus type 1- and 2-encoded thymidine kinases, the K,s were 0.6 and 0.74 ,uM, respectively. Both
FEAU and FMAU were relatively nontoxic for mice, with a 50% lethal dose of >800 mg/kg per day (four
intraperitoneal doses). However, the lethal dose of FEAU for dogs was 100 mg/kg per day (10 intravenous
doses), a dose which is 40- to 80-fold greater than the toxic dose of FMAU. These results suggest that FEAU
is a worthy candidate for further development as an antiherpetic agent.
A series of studies on the structure-activity relationships
of pyrimidine nucleoside analogs indicated that the anti-
herpes simplex virus effect was greatly increased by
2'-fluoro-arabinosyl group substitution and by 5-iodo or
5-methyl group substitution (7, 11, 13). 2'-Fluoro-5-methyl-
1-p-D-arabinofuranosyluracil (FMAU) emerged as the most
potent anti-herpes simplex virus agent in a mouse model
(13). However, subsequent studies indicated that FMAU
caused neurotoxicity in humans (6) and was incorporated
into mammalian cell DNA as well as into viral DNA (8).
Earlier studies of FMAU showed that the 50% effective
doses (ED50s) for inhibiting herpes simplex virus type 1
(HSV-1) and type 2 (HSV-2) replication in vitro are 0.006
and 0.023 ,uM, respectively, whereas the ED50 for inhibiting
the growth of Vero cells is 2.8 ,uM (1). Preliminary studies of
2'-fluoro-5-ethyl-1-,-D-arabinofuranosyluracil (FEAU) indi-
cated that the ED50s for the inhibition of HSV-1 and HSV-2
replication are 0.024 and 0.24 ,uM, respectively. However,
the ED50 for the inhibition of Vero cell growth by FEAU is
>200 FiM (7, 10, 13). FMAU, therefore, is 4- and 10-fold
more potent than FEAU against HSV-1 and HSV-2 replica-
tion, respectively, but 71-fold more toxic than FEAU toward
host cells.
In this study, FEAU is compared with FMAU for cyto-
toxicity in a variety of mammalian cells, kinetic constants for
host and viral thymidine kinases, metabolic properties which
may be modulated to reduce toxicity toward host cells, and
toxicity in several animal species. The detailed synthesis
procedure for FEAU is also reported.
* Corresponding author.
MATERIALS AND METHODS
Synthesis of FEAU. The chemical synthesis of FEAU was
performed by two different procedures (11, 13): (i) catalytic
reduction of 5-vinyl-1-(2'-deoxy-2'-fluoro-,-D-arabinofu-
ranosyl) uracil and (ii) condensation of 5-ethyluracil with
3-O-acetyl-5-O-benzoyl-2-deoxy-2-fluoro-D-arabinofura-
nosyl bromide. The latter method is more practical than the
former. It should be noted that condensation of the silylated
5-ethyluracil with the 2-fluoro-arabinosyl bromide without
the Lewis acid catalyst in methylene chloride at room
temperature yielded and desired P-nucleoside as the major
product, and very little formation of the ax-isomer was
observed. Saponification of the condensation product with
methanolic ammonia yielded FEAU, which was directly
crystallized from a mixture of chloroform and acetone.
A solution of 1,3-di-O-acetyl-5-O-benzoyl-2-deoxy-2-
fluoro-D-ribofuranose (11.9 g, 35 mmol) in dry CH2Cl2 (50
ml) was chilled in an ice bath, and HBr was bubbled in for 30
min. The mixture was kept at 4°C overnight, and the solvent
was removed in vacuo. Traces of acetic acid were removed
by several coevaporations with C6H6, and the residue was
dissolved in CH2Cl2 (200 ml). This solution was added to
5-ethyl-2,4-bis-(trimethylsiloxy)pyrimidine [freshly prepared
by refluxing 5-ethyluracil (4.9 g, 35 mmol) in hexamethyl-
disilazane (20 ml) in the presence of 10 mg of (NH4)2SO4 until
a clear solution was obtained; excess hexamethyldisilazane
was removed in vacuo], and the mixture was stirred for 7
days at room temperature. Aqueous NaHCO3 (30 ml) was
slowly added to the mixture with vigorous stirring, and the
resulting suspension was filtered through a Celite pad. The
filtered solid was thoroughly washed with CH2Cl2. The
organic layer was washed with 100 ml of water two times,
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TABLE 1. ED5os of FEAU and FMAU for inhibiting cell growth
and for inhibiting [3H]dThd incorporation into
DNA in different cells'
Expt ED50 (,uM) of: FEAU/FMAU
FEAU FMAU ED50 ratio
Cell growth
HL-60 cells 2,060 15.4 133.8
Vero cellsb 200 2.8 71.4
[3H]dThd incorporationc
P815 cells 700 14.0 50.0
L1210 cells 630 28.0 22.5
Rat bone marrow cells 3,700 8.9 415
a The ED50s were obtained from the median-effect plot (5) by using a
computer program (2).
b Data are from reference 11.
c [3H]dThd (1 ,Ci, 0.5 pM) was incubated with various concentrations of
FEAU or FMAU by previously described method (3).
dried with Na2SO4, and concentrated to a syrup which was
then purified on a silica gel column with n-hexane-ethyl
acetate (1:1) as the eluent. After concentration of the major
fraction, the residue (10.7 g) was dissolved in ammonia-
saturated methanol (500 ml), and the mixture was kept at
room temperature for 20 h. The solvent was removed by
evaporation, and the residue was crystallized from CHC13-
Me2CO to yield 5.09 g (53.1%) of FEAU; the mp of 163 to
164°C remained unchanged by admixture with an authentic
sample (13). [2-14C]FEAU (1.31 ,uCi/mmol) was synthesized
from a-bromo-FMAU (10) by treatment with [14C]CH3Li.
Experimental details will be reported elsewhere.
Cell lines and viruses. HL-60 cells (a human promyelocytic
cell line) were obtained from R. C. Gallo of the National
Cancer Institute, Bethesda, Md. L1210 and P815 cells
(murine leukemic cell lines) were maintained by serial trans-
plantation in BD2F1 mice. Rat bone marrow cells were
obtained from the femora of CD rats. Vero cells (African
green monkey kidney cell line) were obtained from the
American Type Culture Collection, Rockville, Md., and
maintained in RPMI 1640 medium with 10% fetal calf serum.
Vero cells containing 1 to 1.5 PFU of HSV-1 (strain KOS) or
HSV-2 (strain 333) per cell at 12 h postinfection were used.
Cell growth inhibition studies. HL-60 cells (1.5 x 105/ml)
were grown in RPMI 1640 medium containing 10% fetal calf
serum, 100 ,ug of streptomycin per ml, and 100 U of penicillin
per ml at 37°C in humidified 5% CO2. Different drug concen-
trations were added for a continuous 72-h exposure. Viable
cells were counted by the trypan blue exclusion method.
Incorporation of labeled precursor into DNA. The ED50
for inhibiting the incorporation of [methyl-3H]thymidine
([3H]dThd) (1 ,uCi, 0.15 nmol/ml) into a perchloric acid-
insoluble fraction of DNA was measured by a previously
described method (3). L1210, P815, or rat bone marrow cells
were used. For calculating the Ki for natural nucleoside
precursor incorporation into DNA, constant amounts of
radioactivity in the form of [3H]dThd (1 ,uCi), [6-3H]uridine
([3H]dUrd) (1.0 ,uCi), or [5-3H]cytidine ([3H]dCyd) (0.5 ,uCi)
were added to various amounts of the corresponding
unlabeled compound to make five to six concentrations of
substrate. FEAU (5 ,uM) or FMAU (5 ,uM) was then added
to measure the rates of incorporation inhibition. Incubation
was carried out at 37°C for 15 min. The incubation period
was 2 h for the incorporation of [2-14C]FEAU (10 ,uM, 0.013
p.Ci/ml, or 100 ,uM, 0.13 ,uCi/ml) and [2-14C]FMAU (10 ,uM,
0.12 ,uCi/ml) into the DNAs of L1210 cells, normal Vero
TABLE 2. Inhibition constants of FEAU and FMAU for
inhibiting precursor incorporation into DNA in L1210 cells'
K, (,uM) of: FEAU/FMAU
Substrate varied
FEAU FMAU K ratio
[3H]dThd 1,220 20.0 61
[3H]dUrd 676 6.1 111
[3H]dCyd 332 41.0 8.1
a The inhibitor concentration was 5 pLM for either FEAU or FMAU,
whereas the substrate precursor concentrations were varied. Incubation was
carried out at 37°C for 15 min in the presence of 5 x 106 cells per ml of
incubation mixture. The Lineweaver-Burk plot showed that FEAU was
noncompetitive with respect to [3HldThd and was a competitive inhibitor with
respect to [3HJdUrd or [3H]dCyd, whereas FMAU was a competitive inhibitor
with respect to [3HIdThd, [3H]dUrd, and [3H]dCyd.
cells, and HSV-1-infected Vero cells. The phenol extract
procedure (8) was used to measure the amount of radioac-
tivity incorporated into the DNA.
Thymidine kinases. Thymidine kinases from human acute
myelocytic leukemic cells (cytosolic and mitochondrial) and
from HSV-1- and HSV-2-infected cells were prepared by
previously described methods (1, 9). The ion-exchange pa-
per disk method (9) was used for the t!hymidine kinase
assays.
Datum analysis. The ED50s and Kis were obtained from the
median-effect plot (5) and from the Ki equation (4) by using
a computer program designed to do automated analysis (2).
Animals. Male CD mice (20 to 23 g), male or female
mongrel dogs (10 to 14 kg), and male cynomolgus monkeys
(4 to 5 kg) were purchased from Charles River Breeding
Laboratories, Inc., Kingston, N.Y., Quaker Farm Kennels,
Quakertown, Pa., and Primate Imports, Port Washington,
N.Y., respectively.
RESULTS
The ED50 of FEAU for inhibiting the growth of HL-60
cells was 2,060 ,M, making FEAU 134-fold less toxic than
FMAU (Table 1). This result compared favorably with those
of earlier studies, in which the ED50s were 2.8 ,uM for
FMAU and >200 ,uM for FEAU (7, 11, 12). The ED50s of
FEAU against HSV-1 and HSV-2 were 0.024 and 0.24 ,uM,
respectively. Thus, FEAU is only 4- to 10-fold less potent
than FMAU. These results suggest that FEAU has a favor-
able therapeutic index when compared with FMAU.
The ED50s of FEAU for inhibiting [3H]dThd incorporation
into murine leukemic cell DNA were 50-fold higher in P815
cells and 23-fold higher in L1210 cells than those of FMAU.
In normal rat bone marrow cells, the ED50 for inhibition by
TABLE 3. Incorporation of [2-14C]FEAU or [2-14C]FMAU into
DNA in HSV-1-infected and uninfected cells'
Incorporation (pmol/106 cells per h) of:
Cells
[2-14CJFEAU [2-14C]FMAU
L1210 NDb 0.69
Vero NDb 1.30
HSV-1-infected Vero 0.48 3.40
a The [2-14C]FEAU (0.013 ,uCi/ml) or [2-14C]FMAU (0.12 ,uCi/ml) concen-
tration was 10 ,uM. The incubation conditions were the same as those
described in Table 2, footnote a, except that the incubation time was 2 h.
hND, Not detectable; also not detectable at 100 puM [2-14C]FEAU (0.13
,Ci/ml).
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TABLE 4. FEAU and FMAU as inhibitors and as substrates for thymidine kinases purified from different sources
K, (,uM) with respect % Phosphorylation relative to
Enzyme source to [3H]dlhd of: K, ratio [3H]dThd of: phosphorylation
FEAU FMAU [2-14C]FEAU [2-14C]FMAU ratio
Human acute myelocytic leukemic cells
Cytosolic 150 100 1.5 1.0 81.7
Mitochondrial 176 100 1.7 ND" 219.0
HSV-1 (strain KOS) 0.60 0.59 1.0 82.7 42.0 1.97
HSV-2 (strain 333) 0.74 2.50 0.3 203.2 146.6 1.39
a ND, Not detected.
FEAU was 415-fold higher than for inhibition by FMAU,
suggesting that FEAU will not cause bone marrow depres-
sion (Table 1). Cellular studies of natural precursor incorpo-
ration into the DNA of L1210 cells showed that FEAU had
an 8- to 111-fold lower rate of inhibition of DNA synthesis
than did FMAU (Table 2). While FMAU inhibited [3H]dUrd
incorporation more efficiently than [3H]dCyd incorporation,
FEAU inhibited [3H]dCyd incorporation more efficiently
than [3H]dUrd incorporation or [3H]dThd incorporation.
These results also indicate that FEAU is a weaker inhibitor
of natural nucleoside anabolism than is FMAU in mamma-
lian cells.
There was no detectable [2-14C]FEAU radioactivity incor-
porated into either L1210 cell DNA or Vero cell DNA, but
substantial quantities of [2-14C]FMAU were incorporated
into the DNA of L1210 cells and into the DNA of Vero cells
(Table 3). When HSV-1-infected Vero cells were exposed to
[2-14C]FEAU (10 FLM), however, 0.48 pmol of [2-14C]FEAU
was incorporated into the DNA per 106 cells per h. Under the
same conditions, 7.1-fold more [2-14C]FMAU than [2-
14C]FEAU was incorporated into the DNA of HSV-1-in-
fected Vero cells.
FEAU, like FMAU, exhibited a higher affinity for HSV-1
and HSV-2 thymidine kinases (Ki, 0.6 to 2.5 FiM) than it did
for host cell enzymes (Ki, >150 ,uM). Although FEAU was
a very poor substrate for cytosolic thymidine kinase, it
served as a good substrate for the thymidine kinases pro-
duced by both HSV-1 and HSV-2 (Table 4). In contrast,
FMAU served as a good substrate for mammalian cell
thymidine kinases as well as for the enzymes from HSV-1
and HSV-2 (Table 4).
In vivo experiments (Table 5) indicated that FEAU and
FMAU have different species-related risks of toxicity. In
phase I clinical trials an FMAU dose as low as 0.8 mg/kg per
day (five intravenous doses) caused encephalopathy with
extrapyramidal dysfunction (6); the toxicity of FEAU in
humans is unknown.
DISCUSSION
The present studies indicate that, in various mammalian
systems, FEAU inhibits cell growth and natural nucleoside
incorporation into cellular DNA substantially less than does
FMAU. In addition- the incorporation of labeled FEAU into
cellular DNA is far less than that of labeled FMAU. FEAU,
however, is only 4- to 10-fold less effective in vitro than is
FMAU against HSV-1 and HSV-2.
In cell extracts the Kis of FMAU and FEAU are similar
for mammalian and viral enzymes. The difference in antiviral
potency between FEAU and FMAU is probably due to their
different affinity for virus encoded DNA polymerases. As
indicated in Table 3, [2-14C]FMAU incorporates sevenfold
more radioactivity into HSV-1-infected Vero cells than does
[2-14C]FEAU. This difference in incorporation is comparable
to the magnitude of the difference between their antiherpetic
effects in vitro.
Despite the fact that FEAU is a somewhat weaker anti-
herpetic agent than FMAU, it is still one of the most potent
agents currently available. The most important factor deter-
mining the therapeutic usefulness of FEAU and FMAU is
the degree of toxicity exhibited toward the host. Although
FMAU is more potent against HSV-1 and HSV-2 in vitro
(ED50s, 0.006 M and 0.023 ,uM, respectively) and against
HSV-1 in mice (ED50, 1 mg/kg [intraperitoneal dose]),
FMAU produces encephalopathy in humans at 0.8 mg/kg per
day (five intravenous doses), which severely limits its ther-
apeutic usefulness (6). Encephalopathy does not occur in
mice and rats at FEAU doses as high as 500 mg/kg per day
(five intraperitoneal doses). Nor does encephalopathy occur
in dogs at FEAU doses of 50 mg/kg per day (10 intravenous
doses). These findings indicate that among different animal
TABLE 5. Toxic and lethal doses of FEAU and FMAUI
Animal Toxic dose (mg/kg per day) and effect of: Lethal dose (mg/kg per day) and effect of:
species FEAU FMAU FEAU FMAU
Mouse 800, 4 i.p. doses; no weight 250, 5 i.p. doses; weight loss 1,000, 5 i.p. doses; 1 death/
loss 5 tested
Dog 50, 10 i.v. doses; 0 deaths/ 1.25, 10 i.v. doses; 0 deaths/ 100, 10 i.v. doses; 1 death/ 5, 5 i.v. doses; 2 deaths/
1 tested 2 tested 1 tested 2 tested
Monkey 30, 6 i.v. dosesb; normal 10, 10 i.v. doses; slight
appetite, normal hema- weight loss; 20, 10 i.v.
tological test results doses; weight loss, tremor
a i.p., Intraperitoneal; i.v., intravenous.
b K. F. Soike, Tulane Delta Regional Primate Research Center, Covington, La., personal communication.
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species there are great differences in toxicity between FEAU
and FMAU. The negligible toxic effects of FEAU in various
mammalian cell systems indicate its therapeutic potential.
More detailed in vivo studies are necessary, however, for
further development of this compound.
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